yahoo_financeOriginal article
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Phase 3Neutral
AI Analysis
Summary
Rezolute announced an update on FDA review of Phase 3 sunRIZE study results for a treatment of congenital hyperinsulinism. No specific outcome or timeline details are provided in the available text.
Clinical Trial Data
Phase
Phase 3
Importance:5/10
Sentiment:
0.00
Phase 3FDA ReviewCongenital HyperinsulinismsunRIZE Study
Related Companies
Read the original article
Published by yahoo_finance on September 9, 2026 11:00 AM